As Momma Kliff used to say the more things change the more they remain the same. We couldn’t help but feel this way while listening to Lilly’s (NYSE: LLY) earnings call this morning. Once again, the diabetes drug space is the domain of Lilly and Novo Nordisk (NYSE: NVO). We were also encouraged by some of the comments made by the company related to the coming of a biosimilar short-acting insulin.
Let’s cover that last point first as the company noted they will NOT sue Sanofi (NYSE: SNY) over their short-acting biosimilar. It . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.